Nevertheless, our results suggest that the two sPLA2 inhibitors might be a valid therapeutic approach for FTLD-GRN, and possibly also other neurodegenerative diseases, to restrict neuroinflammation [62]. This evidence concerns the gene PLA2G2A and neurodegenerative disease.